234 related articles for article (PubMed ID: 30564889)
1. Addressing current challenges and future directions in immuno-oncology: expert perspectives from the 2017 NIBIT Foundation Think Tank, Siena, Italy.
Maio M; Coukos G; Ferrone S; Fox BA; Fridman WH; Garcia PL; Lahn M; Provendier O; Russo V; Rüttinger D; Shalabi A; Trajanoski Z; Viallet J; Wolchok JD; Ibrahim R
Cancer Immunol Immunother; 2019 Jan; 68(1):1-9. PubMed ID: 30564889
[TBL] [Abstract][Full Text] [Related]
2. A vision of immuno-oncology: the Siena think tank of the Italian network for tumor biotherapy (NIBIT) foundation.
Maio M; Lahn M; Di Giacomo AM; Covre A; Calabrò L; Ibrahim R; Fox B;
J Exp Clin Cancer Res; 2021 Jul; 40(1):240. PubMed ID: 34301276
[TBL] [Abstract][Full Text] [Related]
3. The Italian Network for Tumor Bio-Immunotherapy (NIBIT) Foundation: ongoing and prospective activities in immuno-oncology.
Di Giacomo AM; Covre A; Giacobini G; Ibrahim R; Lyman J; Natali PG; Maio M
Cancer Immunol Immunother; 2019 Jan; 68(1):143-150. PubMed ID: 30564888
[TBL] [Abstract][Full Text] [Related]
4. Fifteenth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT) on Cancer Bio-Immunotherapy, Siena, Italy, October 5-7, 2017.
Maio M; Lofiego MF; Fazio C; Cannito S; Chiarucci C; Giacobini G; Valente M; Tunici P; Covre A; Russo V
Cancer Immunol Immunother; 2019 Jan; 68(1):151-158. PubMed ID: 30094463
[No Abstract] [Full Text] [Related]
5. Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.
Ascierto PA; Agarwala S; Botti G; Cesano A; Ciliberto G; Davies MA; Demaria S; Dummer R; Eggermont AM; Ferrone S; Fu YX; Gajewski TF; Garbe C; Huber V; Khleif S; Krauthammer M; Lo RS; Masucci G; Palmieri G; Postow M; Puzanov I; Silk A; Spranger S; Stroncek DF; Tarhini A; Taube JM; Testori A; Wang E; Wargo JA; Yee C; Zarour H; Zitvogel L; Fox BA; Mozzillo N; Marincola FM; Thurin M
J Transl Med; 2016 Nov; 14(1):313. PubMed ID: 27846884
[TBL] [Abstract][Full Text] [Related]
6. Developing and validating model systems for immuno-oncology.
McCarthy CE; Zahir N; Eljanne M; Sharon E; Voest EE; Palucka K
Cancer Cell; 2021 Aug; 39(8):1018-1022. PubMed ID: 34115988
[TBL] [Abstract][Full Text] [Related]
7. SITC 2018 workshop report: Immuno-Oncology Biomarkers: State of the Art.
Butterfield LH; Disis ML; Fox BA; Kaufman DR; Khleif SN; Wang E;
J Immunother Cancer; 2018 Dec; 6(1):138. PubMed ID: 30514399
[TBL] [Abstract][Full Text] [Related]
8. Second- and third-generation drugs for immuno-oncology treatment-The more the better?
Dempke WCM; Fenchel K; Uciechowski P; Dale SP
Eur J Cancer; 2017 Mar; 74():55-72. PubMed ID: 28335888
[TBL] [Abstract][Full Text] [Related]
9. [The revolution of immuno-oncology therapy: specificities for the physicians].
Dubois M; Ardin C; André F; Scherpereel A; Mortier L
Med Sci (Paris); 2019 Dec; 35(12):946-948. PubMed ID: 31903898
[TBL] [Abstract][Full Text] [Related]
10. Perspectives in immunotherapy: meeting report from the Immunotherapy Bridge (29-30 November, 2017, Naples, Italy).
Ascierto PA; Brugarolas J; Buonaguro L; Butterfield LH; Carbone D; Daniele B; Ferris R; Fox BA; Galon J; Gridelli C; Kaufman HL; Klebanoff CA; Melero I; Nathan P; Paulos CM; Ruella M; Sullivan R; Zarour H; Puzanov I
J Immunother Cancer; 2018 Jul; 6(1):69. PubMed ID: 29996914
[TBL] [Abstract][Full Text] [Related]
11. Next-generation immuno-oncology agents: current momentum shifts in cancer immunotherapy.
Pan C; Liu H; Robins E; Song W; Liu D; Li Z; Zheng L
J Hematol Oncol; 2020 Apr; 13(1):29. PubMed ID: 32245497
[TBL] [Abstract][Full Text] [Related]
12. From New directions in immuno-oncology.
Romero D
Nat Rev Clin Oncol; 2019 Nov; 16(11):660. PubMed ID: 31541198
[No Abstract] [Full Text] [Related]
13. Liquid biopsy in the era of immuno-oncology: is it ready for prime-time use for cancer patients?
Hofman P; Heeke S; Alix-Panabières C; Pantel K
Ann Oncol; 2019 Sep; 30(9):1448-1459. PubMed ID: 31228184
[TBL] [Abstract][Full Text] [Related]
14. Personalized Immuno-Oncology.
Jain KK
Med Princ Pract; 2021; 30(1):1-16. PubMed ID: 32841942
[TBL] [Abstract][Full Text] [Related]
15. Clinical development of immuno-oncology in China.
Wu DW; Huang HY; Tang Y; Zhao Y; Yang ZM; Wang J; Wang SH; Yu Y; Fang Y; Fang H; Bai Y; Sun C; Fan Q; Yu AQ; Wang HL; Du CX; Chen K; Huang MD; Zhang Y; Li N; Xu BH; Sun Y; He J
Lancet Oncol; 2020 Aug; 21(8):1013-1016. PubMed ID: 32758460
[No Abstract] [Full Text] [Related]
16. Development of an Anti-canine PD-L1 Antibody and Caninized PD-L1 Mouse Model as Translational Research Tools for the Study of Immunotherapy in Humans.
Oh W; Kim AMJ; Dhawan D; Kirkham PM; Ostafe R; Franco J; Aryal UK; Carnahan RH; Patsekin V; Robinson JP; Knapp DW; Lim SO
Cancer Res Commun; 2023 May; 3(5):860-873. PubMed ID: 37377896
[TBL] [Abstract][Full Text] [Related]
17. Immuno-oncology for surgeons.
Lee SL; Al-Shamkhani A; Mirnezami A
Br J Surg; 2019 Sep; 106(10):1273-1282. PubMed ID: 31318438
[TBL] [Abstract][Full Text] [Related]
18. The hubris and humility of cancer pharmacology in the post immuno-oncology era.
Lazo JS
Pharmacol Res Perspect; 2019 Dec; 7(6):e00527. PubMed ID: 31624635
[TBL] [Abstract][Full Text] [Related]
19. Goals and objectives of the Italian Network for Tumor Biotherapy (NIBIT).
Russo V; Amadori A; Bregni M; Calabrò L; Colombo MP; Di Nicola M; Ferrucci PF; Proietti E; Maio M; Bellone M
Cytokine Growth Factor Rev; 2017 Aug; 36():1-3. PubMed ID: 28634022
[TBL] [Abstract][Full Text] [Related]
20. Cancer research using organoid technology.
Kretzschmar K
J Mol Med (Berl); 2021 Apr; 99(4):501-515. PubMed ID: 33057820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
